Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
The innovation is particularly suited for bone and cartilage repair
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The goal is to better support drug developers as programs move from laboratory research into clinical trials
Subscribe To Our Newsletter & Stay Updated
